THE GIBSON GROUP, LLC for ENDO PHARMACEUTICALS INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Issues relating to incentives for life sciences research. H.R. 523/S. 232: Protect Medical Innovation Act of 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH H GIBSON | — |
Copyright/Patent/Trademark CPT
Oversight of implementation of the America Invents Act. Issues relating to patent settlements, including S. 214: Preserve Access to Affordable Generics Act. H.R. 3309: Innovation Act. S. 1720: Patent Transparency and Improvements Act of 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH H GIBSON | — |
Health Issues HCR
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates. Issues relating to health information technology. H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013. Compounding and drug supply chain legislation. H.R. 3204: Drug Quality and Security Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for vacuum erection systems.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOSEPH H GIBSON | Counsel, House Judiciary Comm. '95-'97 |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.